Organization (Academic)
Norwegian School of Sport Sciences
ClinicalTrials.gov lists Norwegian School of Sport Sciences as lead sponsor of 46 trials. It has 6 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers Norwegian School of Sport Sciences: 46 lead-sponsored trials and 1 legal-entity registration.
Disease areas (73)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Feeding and Eating Disorders | 13 |
| Obesity | 6 |
| Insulin Resistance | 5 |
| Anxiety Disorders | 4 |
| Prostatic Neoplasms | 4 |
Showing 5 of 73 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 7 |
| 2023 | 3 |
| 2022 | 9 |
| 2021 | 4 |
| 2020 | 12 |
| 2019 | 6 |
| 2018 | 3 |
| 2017 | 3 |
Showing 10 of 20 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (6)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Aerobic exercise | Lymphoma | Not reported | 1 |
| Aerobic exercise | Radiation Injuries | Not reported | 1 |
| Aerobic exercise | Drug-Related Side Effects and Adverse Reactions | Not reported | 1 |
| Aerobic exercise | Cardiotoxicity | Not reported | 1 |
| Aerobic exercise | Breast Neoplasms | Not reported | 1 |
Showing 5 of 6 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Testosterone Undecanoate | 1 |
| ZOLADEX | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 45% hit target (n=20) | 32% on time (n=19) |
Journals published in (170)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| British journal of sports medicine | 14 |
| Medicine and science in sports and exercise | 9 |
| International urogynecology journal | 8 |
| Scandinavian journal of medicine & science in sports | 8 |
| Sports medicine (Auckland, N.Z.) | 7 |
Showing 5 of 170 journals.
Organization relationships (26)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Norwegian University of Science and Technology | Co sponsors trial with | 4 |
| Sunnaas Rehabilitation Hospital | Co sponsors trial with | 2 |
| University of Tromso | Co sponsors trial with | 2 |
| Loma Linda University | Co sponsors trial with | 1 |
| HAN University of Applied Sciences | Co sponsors trial with | 1 |
Showing 5 of 26 relationships.
Latest dated events (92)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2028-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 92 events.
Biomarker capability evidence (16)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CCNG1 | Trial sponsor | Named in trial inclusion criteria |
| FBLN5 | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial exclusion criteria |
| ATP4A | Trial sponsor | Named in trial exclusion criteria |
| FBLN5 | Trial sponsor | Exploratory endpoint in a trial |
Showing 5 of 16 evidence rows.
Biomarkers this organization publishes on (162)
Shown in this order: most publications first.
Showing 5 of 162 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.